16 Jan 24
16 Jan 24
Biocomposites expands its international presence by opening new sales and distribution office in Italy
  • Biocomposites SRL will support sales of STIMULAN, NanoBone, genex and SYNICEM Spacers throughout Italy
  • New team has been hired and first sales have already taken place
  • Keele, UK, 16 January 2024 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    21 Nov 23
    21 Nov 23
    Biocomposites expands its product portfolio with the launch of SYNICEM™ spacers in the UK
  • SYNICEM™ hip, knee and shoulder spacers are preformed and loaded with gentamicin to maintain space and aid treatment of infection.
  • Already successfully used in UK patients as part of their infection treatment strategies
  • Keele, UK, 21 November 2023 – Biocomposites, an international medical devices company that engineers, manufactures and…...
    Pioneering calcium compounds

    Innovation is at the very heart of what we do, resulting in over 100 grants and registrations.

    Musculoskeletal infection

    Growth of antibiotic-resistant biofilms continues to outpace the development of new antibiotics.

    Dedicated to quality

    Manufacturing, processing, testing and distribution are all handled in-house

    Singular focus

    Deep expertise and singular focus on calcium compound medical devices

    Your specialty

    Access case studies, clinical and pre-clinical papers for musculoskeletal infection, trauma and spine to see how we are innovating across a wide range of clinical applications to help surgeons and their patients.

    Musculoskeletal infections

    Musculoskeletal infections, including infected non-unions, osteomyelitis and periprosthetic joint infections, are one of the biggest healthcare challenges of the 21st century.

    As the rapid growth of antibiotic-resistant strains and biofilms continues to outpace the development of new antibiotics and antibiotic strategies, care delivery is becoming increasingly challenging and complicated.


    Bone and joint trauma, such as fractures and dislocations, are common and vary in severity from single fractures to multiple, life-threatening musculoskeletal injuries.

    The most clinically challenging of these for the surgeon, and those that have the most socioeconomic burden, are open fractures. These often involve damage to the surrounding soft tissue, resulting in complications such as tissue and deep bone infection or long-term non-union.


    The popularity of spine surgery differs around the world. The number of procedures performed in the USA is double the number performed in Western Europe, Canada and Australia combined, and five times the number in the UK.

    In the USA, the number of spinal fusion procedures increased by 64% between 2002 and 2014, from approximately 268,000 to 414,000. The average cost per procedure has increased from $15,868 to $28,954 over the same period and was more than $12 billion in total in 2014.

    Why Biocomposites?

    At Biocomposites, we are pioneering calcium compound devices to regenerate and repair bone and soft tissue. With over 30 years’ experience of manipulating the surface chemistry and crystalline properties of calcium compounds, we engineer and manufacture products at the forefront of calcium technology.

    • Singular focus
    • Proprietary technology
    • Dedicated to quality
    Learn more